Biomimetic transfer hydrogenation of 2-alkoxy- and 2-aryloxyketones with iron–porphyrin catalysts
摘要:
In situ generated iron porphyrins are applied as homogeneous catalysts in the transfer hydrogenation of a-substituted ketones. Using 2-propanol as hydrogen donor various protected 1, 2-hydroxyketones are reduced to the corresponding mono-substituted 1,2-diols in good to excellent yield. Under optimized reaction conditions catalyst turnover frequencies up to 2500 h(-1) have been achieved. (c) 2008 Elsevier Ltd. All rights reserved.
Biomimetic transfer hydrogenation of 2-alkoxy- and 2-aryloxyketones with iron–porphyrin catalysts
摘要:
In situ generated iron porphyrins are applied as homogeneous catalysts in the transfer hydrogenation of a-substituted ketones. Using 2-propanol as hydrogen donor various protected 1, 2-hydroxyketones are reduced to the corresponding mono-substituted 1,2-diols in good to excellent yield. Under optimized reaction conditions catalyst turnover frequencies up to 2500 h(-1) have been achieved. (c) 2008 Elsevier Ltd. All rights reserved.
[EN] NOVEL COMPOUNDS FOR SKIN LIGHTENING<br/>[FR] NOUVEAUX COMPOSÉS POUR L'ÉCLAIRCISSEMENT DE LA PEAU
申请人:UNILEVER GLOBAL IP LTD
公开号:WO2021037759A1
公开(公告)日:2021-03-04
A novel compound is disclosed. Skin lightening composition comprising said compound and method of skin lightening is disclosed too. In addition, method of synthesizing said novel compound is disclosed.
[EN] NOVEL COMPOUNDS FOR SKIN LIGHTENING<br/>[FR] NOUVEAUX COMPOSÉS POUR ÉCLAIRCISSEMENT DE LA PEAU
申请人:UNILEVER GLOBAL IP LTD
公开号:WO2021037750A1
公开(公告)日:2021-03-04
Novel compounds are disclosed. Skin lightening composition comprising said compounds and method of skin lightening is disclosed too. In addition, method of synthesizing said novel compounds are disclosed.
Nicotine in therapeutic angiogenesis and vasculogenesis
申请人:Cooke John
公开号:US20060182731A1
公开(公告)日:2006-08-17
The present invention features methods for induction of angiogenesis by administration of nicotine or other nicotine receptor agonist. Induction of angiogenesis by the methods of the invention can be used in therapeutic angiogenesis in, for example, treatment of ischemic syndromes such as coronary or peripheral arterial disease.